Olumiant offers hope to patients with rheumatoid arthritis

By Brian Buntz | July 21, 2021

Olumiant

FDA has indicated Lilly‘s OLUMIANT (baricitinib) to treat adult patients with moderately to severely active rheumatoid arthritis. In particular, the agency has recommended the drug for patients with an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

In June, Lilly and its partner Incyte announced that the drug appeared to reduce pain, morning joint stiffness and overall physical function in post-hoc analyses comparing it to Humira and placebo.

Lilly and Incyte are working to expand the indication for the drug. FDA recently delayed the PDUFA action data for a supplemental new drug application for Olumiant for severe atopic dermatitis.

FDA has also granted an emergency use authorization to the drug in combination with remdesivir to treat COVID-19 in hospitalized patients.

Filed Under: Rheumatology
Tagged With: Lilly, Olumiant, rheumatoid arthritis

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].